Newsroom

CHICAGO--(BUSINESS WIRE)--The FECK Awards, a powerful new national recognition program celebrating individuals who embody the transformative values of Forgiveness, Empathy, Compassion, and Kindness, today revealed the winners of its inaugural awards. Created by Chaz Ebert, CEO of Ebert Digital LLC and a longtime champion of empathy in storytelling and leadership, the FECK Awards were inspired by the principles outlined in her book It’s Time to Give a FECK: Elevating Humanity Through Forgiveness...

ATLANTA--(BUSINESS WIRE)--Wally Mlynarski has been named CEO of Elavon, a wholly owned subsidiary of U.S. Bank, delivering secure, scalable payments solutions and dedicated support to businesses across the United States, Europe and Canada. Mlynarski most recently led merchant services and receivables at Bank of America. He previously spent seven years with U.S. Bank supporting Elavon, where he held leadership roles including chief product officer. In his new role, Mlynarski will report to Mark...

SEATTLE--(BUSINESS WIRE)--Dropzone AI launches AI Threat Hunting, enhancing its Agentic SOC platform to help security teams proactively and continuously detect threats....

DALLAS--(BUSINESS WIRE)--LTK, the company that turned influence into a global economy, today introduced Quick Collabs, a new feature within the LTK Brand Platform designed to make it easier and faster for brands and creators to work together. Designed to remove the friction that slows creator marketing down, Quick Collabs is the fastest, lowest-commitment way to activate creators on LTK. Quick Collabs are flat-fee campaigns that brands can launch in minutes, enabling creators to opt in and get...

INCHEON, Corée--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. a annoncé aujourd’hui la conclusion d’un accord mondial de licence, de développement et de commercialisation (DCA) avec Sandoz, portant sur un maximum de cinq candidats biosimilaires actuellement en développement au sein de Samsung Bioepis, dont SB36, un candidat biosimilaire ayant pour produit de référence Entyvio1 (vedolizumab). Les autres modalités de l’accord demeurent confidentielles. Aux termes de l’accord, Samsung Bioepis sera re...

INCHEON, Korea--(BUSINESS WIRE)--Vandaag maakte Samsung Bioepis Co., Ltd. bekend dat het bedrijf een wereldwijde DCA-licentie (Development & Commercialization Agreement) heeft gesloten met Sandoz voor in totaal vijf biosimilaire kandidaatgeneesmiddelen die momenteel door Samsung Bioepis worden ontwikkeld, waaronder SB36, een biosimilair kandidaatgeneesmiddel gelijkwaardig aan Entyvio1 (vedolizumab). Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts al...

INCHEON, Corea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. oggi ha annunciato la sigla con Sandoz di un accordo di licenza, sviluppo e commercializzazione (DCA) globale che riguarderà fino a cinque candidati biosimilari in corso di sviluppo da parte di Samsung Bioepis, tra cui SB36, un candidato biosimilare di Entyvio1 (vedolizumab). Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodità...

INCHEON, Corea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. anuncia que la empresa ha firmado un acuerdo global de licencia, desarrollo y comercialización (DCA, por sus siglas en inglés) con Sandoz para un máximo de cinco candidatos a biosimilares que Samsung Bioepis tiene en fase de desarrollo, incluido el SB36, un candidato a biosimilar basado en Entyvio1 (vedolizumab). Los demás términos del acuerdo son confidenciales. Según los términos del acuerdo, Samsung Bioepis se encargará del desarroll...

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Five9, Inc. (NASDAQ: FIVN). If you currently own shares of Five9, Inc. stock, please visit the firm’s website at https://rosenlegal.com/submit-form/?case_id=32046 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at case@rosenlegal.com. Why Rosen Law: We en...

INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. gab heute bekannt, dass das Unternehmen eine globale Lizenz-, Entwicklungs- und Vermarktungsvereinbarung (DCA) mit Sandoz über bis zu fünf von Samsung Bioepis entwickelte Biosimilar-Kandidaten geschlossen hat, darunter SB36, ein Biosimilar-Kandidat, der auf Entyvio1 (Vedolizumab) basiert. Die weiteren Bedingungen der Vereinbarung bleiben vertraulich. Gemäß den Vertragsbedingungen wird Samsung Bioepis für die Entwicklung, die behördliche...